Wilmington, N.C. —January 7, 2008— Inclinix, Inc., an enrollment contract research that the company has closed $10 million in expansion funding from Frontier Capital. Frontier is a private equity firm providing growth equity to business services companies.
Inclinix accelerates the clinical trials of new drugs by delivering qualified doctors and patients for enrollment. The company will use the investment to fund further enhancement of its proprietary enrollment processes and technologies. Inclinix will also add sales, marketing, and service delivery resources and expand its corporate facilities.
“We are excited about this investment, which will help us continue the tremendous growth of our company,” said J. Tobin Geatz, president and CEO. “Inclinix has grown 40 percent annually the past three years and sought capital to better serve our customers and accelerate our expansion. We will continue to provide industry-leading enrollment services and technologies to some of the world’s largest pharmaceutical, biopharmaceutical and medical device companies on a global basis.”
Michael Ramich, partner at Frontier Capital, said, “After watching Inclinix’s progress and growth over the past few years, we have been significantly impressed. They have proven expertise in delivering enrollment solutions to the leading sponsors conducting clinical research today. We are pleased to make this commitment and look forward to supporting Inclinix’s continued growth and development as a leading CRO.”
Founded in 1999, Inclinix, Inc., is the industry’s Enrollment CRO. Inclinix’s IQMÔ Intelligent Enrollment process uses technology to amplify traditional services and is proven to accelerate trials for pharmaceutical, biotechnology and medical-device organizations. In addition to its clinical research-related offerings, Inclinix provides strategic medical marketing communications and adherence services to the healthcare industry. For more information on Inclinix, visit www.inclinix.com